Biotech

All Articles

BMS centers bispecific months after submitting to operate period 3 trial

.Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halt...

Charles Baum takes control of Terremoto as CEO

.Charles Baum, M.D., Ph.D., who looked after Mirati Therapeutics' $ 5.8 billion sale to Bristol Myer...

Asarina to shut after attempts to companion Tourette's drug fall short

.After communicating to greater than 200 providers to companion a Tourette syndrome treatment that r...

Novartis markers $150M ahead of time bispecifics handle Dren Bio

.Novartis has actually had some bad luck along with bispecific antibodies in the past, but evaluatin...

AstraZeneca plants an EGFR tree along with Pinetree package worth $45M

.Pinetree Therapeutics are going to help AstraZeneca vegetation some plants in its own pipe with a b...

GRO collects $60M series B to take gout pain therapy right into center

.GRO Biosciences has actually ended the week with an extra $60.3 thousand in the banking company, wh...

Chutes &amp Ladders-- Gilead's Merdad Parsey goes, Cassava sheds CEO

.Welcome to today's Chutes &amp Ladders, our roundup of substantial management hirings, shootings an...